Why this stood out: This is a rare 3-insider cluster at a mega-cap with the CEO's first open-market buy since becoming CEO (per Guggenheim's Simeon Siegel). Lead Director Tim Cook (Apple CEO) added another $1.06M — his 3rd major Nike buy in 4 months, bringing his stake to 130,480 shares. All three insiders bought within $0.20 of each other near the 52-week low ($42.09). Nike is mid-turnaround under Hill (hired Oct 2024) amid China softness and tariff pressures. For a blue-chip, insider buying of this size/coordination near multi-year lows is a textbook confidence signal. Stock is only ~9% above cluster buy levels → still an opportunity.

Why this stood out: HeartBeam makes a credit-card-sized 3D ECG device (first cleared by FDA Dec 2024). After a brutal -66% YTD decline and an offering priced at $0.80, every major director plus the CFO wrote personal checks into the offering. The 750,000-share buy by Mark Strome alone is 4× his prior holdings; his follow-on ownership totals 3.65M shares. Treat as speculative/high-risk micro-cap, but the breadth of insider participation is unusual and suggests the board sees value at these levels.

Why this stood out: Allison's $2.7M buy is 10× larger than his January purchase and his biggest single open-market buy in this reporting cycle — arriving right after Q1 2026 earnings (EPS $0.60 beat, but one $92.1M non-performing loan relationship disclosed) knocked the stock from $30+ to $27. Notable sell-then-buy-bigger pattern: sold 110K at $30 last August, now buying back 100K at $27 — implicit $300K+ upside-targeting move. Allison already owns 5.8M shares directly; this is a conviction add, not a stake-establishing buy. Regional-bank CEO doubling down on own shares at a 10% discount to 52-wk high, just after a credit hiccup, is a classic contrarian insider signal.

Why this stands out: This is a pure conviction signal — Steven Gunby (who has led FCN since 2014 and just had his contract extended per yesterday's O'Dwyer's item) spent $1.13M of his own capital on the open market on April 21. It is the only insider purchase at FTI Consulting in the trailing 12 months, and the largest by any FCN insider over that window. The market immediately reprised the stock +4.3%. Gunby already holds meaningful equity, so this is a conviction add rather than a stake-establishing buy. FCN is a mid-cap consulting firm with historically low insider activity — when the CEO does act, the signal-to-noise ratio is high. Caveat: consulting cycles can be lumpy; watch Q2 bookings.

Why this stands out (with caveats): Arxis IPO'd on Nasdaq April 16, 2026 at $28 (top of upsized range, $1.13B raised). Seven insiders — directors, CAO, and senior managers — collectively put $5.64M of their own cash into shares at the offering price on the April 17 closing. Shares surged +36% on debut and now trade at ~$36.25, already marking their positions up ~29%. Important caveat: these are IPO allocations at the offering price, not surprise open-market bids, so the signal quality is weaker than a typical conviction buy. That said, seven insiders each staking $125K–$1.7M of personal capital in an aerospace/defense IPO is above-average participation and — given Arxis supplies mission-critical components for defense, space and commercial aerospace platforms (about 70% defense/aero mix in 2025) — the cluster is worth tracking as a secular-tailwind play.

Why this stands out: What started as a single CEO conviction buy on April 21 ($259K after a 23% drawdown from his February buy) has expanded over 72 hours into a 5-insider cluster — VP Tarantino and VP Callahan bought ~$100K each on April 22, and VP Htwe ($197K) plus EVP Wrocklage ($122K) joined on April 23. That's six insiders, ~$1.28M, in just 72 days, with most of it packed into a 3-day window. More importantly, the market appears to be responding: BMI has recovered from $114.70 (VP Tarantino's entry) to $123.07 as the cluster built, and the EVP on April 23 was willing to pay $122.35 — the highest price of the cluster — which is the opposite of what you see when insiders are merely defending a stock. BMI runs water meters and smart metering (AMI), a defensive SaaS-like recurring-revenue category. Caveat: Bockhorst's February buy is already ~20% underwater; a follow-through rally is not yet confirmed.

Why this stands out: Three executives — CEO, Board Director, and CAO — all bought on the same day (April 16) right after Q1 2026 earnings. Despite beating EPS by 19% ($0.31 vs $0.26) and crushing revenue ($779M vs $713M), the stock sits at 6.4x P/E vs a sector average of 22x. All 5 insider transactions in the past 6 months have been purchases (zero sales). Cluster buying right post-earnings at multi-year lows.

Why this stands out (with caveats): Tom Ward is the founder of MACH Natural Resources and invested $2M buying into a secondary offering at $13.05. The fact that a major insider participates in a secondary rather than letting it dilute him is a positive signal. However, buying into a company-sponsored secondary carries less conviction than pure open-market purchases. Analyst consensus target is $18.50, implying ~42% upside.

Why this stands out: CEO Angeliki Frangou has made 17 open-market purchases over 6 months, totaling $1.43M of personal capital. While each individual purchase is modest, the consistent accumulation pattern suggests sustained conviction. This type of steady, uninterrupted buying is often more meaningful than a one-time bet — it indicates the CEO believes the stock is undervalued at every level.

Why this stands out: Chairman Gregg Williams has deployed nearly $20 million of personal capital into Vivani Medical across 13 separate transactions since late 2024. While the repeated pattern reduces the 'shock' factor, the sheer sustained scale is extraordinary for a micro-cap biotech at $1.26/share. Vivani develops miniaturized implantable drug delivery devices. Caveats: Many purchases appear to be in private placements. High risk.

Why this stands out: A CEO buying ~$75K in their own micro-cap stock at penny prices is notable because the proportional commitment relative to the company's market cap is significant. Worksport makes solar-integrated truck bed covers — a niche clean energy play. Treat this as speculative/high-risk.